to the European Medicines Agency (EMEA) for Focetria as an H5N1 . Focetria is a pandemic influenza vaccine, surface antigen, inactivated. Focetria. Scientific conclusions and grounds recommending the variation to the terms of the marketing EMEA/H/C//PSUV/ following assessment of the H1N1 data available with Focetria in children, In the context of variation EMEA/H/C//II/ (commission.

Author: Nitaur Mezinris
Country: Sao Tome and Principe
Language: English (Spanish)
Genre: Health and Food
Published (Last): 13 August 2006
Pages: 448
PDF File Size: 2.83 Mb
ePub File Size: 2.65 Mb
ISBN: 179-9-56723-173-6
Downloads: 73940
Price: Free* [*Free Regsitration Required]
Uploader: Mezidal

Pandemic influenza: news archive

The marketing authorisation for Focetria has been expired following the marketing-authorisation holder’s decision not to apply for a renewal. More detail is available in the summary of product characteristics.

Skip to main content. Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation. Table of contents Overview Authorisation details Product information Assessment history.


Product details Name Focetria. Emes virus surface antigens haemagglutinin and neuraminidase of strain: You are therefore advised to be selective about which sections or pages you wish to print.

Prophylaxis of influenza focegria by A H1N1v virus. Focetria should be used in accordance with official guidance. Changes since initial authorisation of medicine List item.

Pandemic influenza: news archive | European Medicines Agency

Initial marketing-authorisation documents List item. More information on Focetria. How useful was this page?

Leave this field blank. International non-proprietary name INN or common name.

Focetria | European Medicines Agency

Influenza, Human Immunization Disease Outbreaks. Anatomical therapeutic chemical ATC code.

Novartis Vaccines and Diagnostics S. Date of issue of marketing authorisation valid throughout the European Union.